Literature DB >> 29987426

Clinical characteristics and risk factors of infections in patients with systemic lupus erythematosus.

Chengcheng Hou1, Ou Jin2, Xi Zhang2.   

Abstract

To investigate the clinical characteristics of infection in SLE patients and analyze the risk factors of infection. A retrospective analysis method was used and the data were collected from 173 case times of 142 hospitalized patients. We found the incidence rate of infections in SLE was 50.7%. The most common infection sites were lungs, followed by upper respiratory tracts and urinary tracts. The most common pathogens were bacteria, followed by fungi. The infection-associated risk factors were duration of hospitalization, lupus activity state, the use of high-dose corticosteroids and immunosuppressive agents, the low serum level of complements 3 and 4 (C3 and C4), fever, the high level of erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP), the abnormality of white blood cell (< 4 × 109/L or > 10 × 109/L), and the low level of albumin (P < 0.05 or P < 0.001). The independent risk factors for SLE patients with infection consist of the abnormality of white blood cells, the high level of CRP, the low serum level of C4, and longtime hospitalization. Attention should be paid to the risk factors of infection, and treatment to enhance immunity should be carried out to reduce the chance of infection.

Entities:  

Keywords:  Infection; Infection site; Pathogens; Risk factors; Systemic lupus erythematosus

Mesh:

Substances:

Year:  2018        PMID: 29987426     DOI: 10.1007/s10067-018-4198-8

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  23 in total

1.  Infection in Southern Chinese Patients with Systemic Lupus Erythematosus: Spectrum, Drug Resistance, Outcomes, and Risk Factors.

Authors:  Dongying Chen; Jingyi Xie; Haihong Chen; Ying Yang; Zhongping Zhan; Liuqin Liang; Xiuyan Yang
Journal:  J Rheumatol       Date:  2016-06-15       Impact factor: 4.666

2.  Infections in systemic lupus erythematosus: a prospective and controlled study of 110 patients.

Authors:  X Bosch; A Guilabert; L Pallarés; R Cerveral; M Ramos-Casals; A Bové; M Ingelmo; J Font
Journal:  Lupus       Date:  2006       Impact factor: 2.911

3.  Incidence and risk factors of infection in a single cohort of 110 adults with systemic lupus erythematosus.

Authors:  Su Jin Jeong; Heekyung Choi; Han Sung Lee; Sang Hoon Han; Bum Sik Chin; Ji-Hyeon Baek; Chang Oh Kim; Jun Yong Choi; Young Goo Song; June Myung Kim
Journal:  Scand J Infect Dis       Date:  2009

4.  Serious infections in British patients with systemic lupus erythematosus: hospitalisations and mortality.

Authors:  F Goldblatt; S Chambers; A Rahman; D A Isenberg
Journal:  Lupus       Date:  2009-07       Impact factor: 2.911

5.  Clinical presentations and outcomes of systemic lupus erythematosus patients with infection admitted to the intensive care unit.

Authors:  B K Han; R Bhatia; P Traisak; K Hunter; B Milcarek; C Schorr; H Eid; D Feinstein; P Cronin; S L Kolasinski
Journal:  Lupus       Date:  2013-05-20       Impact factor: 2.911

6.  Impaired phagocytosis and susceptibility to infection in pediatric-onset systemic lupus erythematosus.

Authors:  S-A Wu; K-W Yeh; W-I Lee; T-C Yao; M-L Kuo; B Huang; J-L Huang
Journal:  Lupus       Date:  2013-01-31       Impact factor: 2.911

7.  Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients.

Authors:  Ricard Cervera; Munther A Khamashta; Josep Font; Gian Domenico Sebastiani; Antonio Gil; Paz Lavilla; Juan Carlos Mejía; A Olcay Aydintug; Hanna Chwalinska-Sadowska; Enrique de Ramón; Antonio Fernández-Nebro; Mauro Galeazzi; Merete Valen; Alessandro Mathieu; Frédéric Houssiau; Natividad Caro; Paula Alba; Manuel Ramos-Casals; Miguel Ingelmo; Graham R V Hughes
Journal:  Medicine (Baltimore)       Date:  2003-09       Impact factor: 1.889

8.  Infection of Female BWF1 Lupus Mice with Malaria Parasite Attenuates B Cell Autoreactivity by Modulating the CXCL12/CXCR4 Axis and Its Downstream Signals PI3K/AKT, NFκB and ERK.

Authors:  Gamal Badr; Ayat Sayed; Mostafa A Abdel-Maksoud; Amany O Mohamed; Azza El-Amir; Fathy A Abdel-Ghaffar; Saleh Al-Quraishy; Mohamed H Mahmoud
Journal:  PLoS One       Date:  2015-04-24       Impact factor: 3.240

9.  Predictors of major infections in systemic lupus erythematosus.

Authors:  Guillermo Ruiz-Irastorza; Nerea Olivares; Ioana Ruiz-Arruza; Agustin Martinez-Berriotxoa; Maria-Victoria Egurbide; Ciriaco Aguirre
Journal:  Arthritis Res Ther       Date:  2009-07-15       Impact factor: 5.156

10.  Systemic lupus erythematosus (SLE) at the Kenyatta National Hospital.

Authors:  Paul Etau Ekwom
Journal:  Clin Rheumatol       Date:  2013-03-03       Impact factor: 3.650

View more
  4 in total

1.  Infection-related hospitalization after intensive immunosuppressive therapy among lupus nephritis and ANCA glomerulonephritis patients.

Authors:  Peihong Yin; Jianbo Li; Qiong Wen; Yagui Qiu; Wenyi Liang; Junxian Wang; Jing Yu; Zhong Zhong; Xiao Yang; Xueqing Yu; Qing Ye; Fengxian Huang
Journal:  Ren Fail       Date:  2020-11       Impact factor: 2.606

2.  Associated clinical factors for serious infections in patients with systemic lupus erythematosus.

Authors:  Ju-Yang Jung; Dukyong Yoon; Young Choi; Hyoun-Ah Kim; Chang-Hee Suh
Journal:  Sci Rep       Date:  2019-07-04       Impact factor: 4.379

Review 3.  Dysregulation of immunity in COVID-19 and SLE.

Authors:  Seyyed Sina Hejazian; Seyyedeh Mina Hejazian; Farahnoosh Farnood; Sima Abedi Azar
Journal:  Inflammopharmacology       Date:  2022-08-26       Impact factor: 5.093

4.  Rapid and precise diagnosis of pneumonia coinfected by Pneumocystis jirovecii and Aspergillus fumigatus assisted by next-generation sequencing in a patient with systemic lupus erythematosus: a case report.

Authors:  Yili Chen; Lu Ai; Yingqun Zhou; Yating Zhao; Jianyu Huang; Wen Tang; Yujian Liang
Journal:  Ann Clin Microbiol Antimicrob       Date:  2021-06-26       Impact factor: 3.944

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.